Download PDF

1. Company Snapshot

1.a. Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.


It also has a research collaboration agreement with Pfizer Inc.and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc.The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on BEAM

Beam Therapeutics' recent performance was negatively impacted by a wider-than-expected loss of $1.09 per share in Q4, despite topping revenue estimates. The company incurred a narrower-than-expected loss, but the magnitude of the loss overshadowed the positive news. Furthermore, the lack of significant updates on pipeline development and the absence of any new product approvals or launches in the recent earnings release contributed to the negative sentiment. The company's cash runway is expected to support operating plans into 2027, but this does not offset the current negative sentiment.

1.c. Company Highlights

2. Beam Therapeutics' Earnings Report: A Deeper Dive into Financials and Pipeline Progress

Beam Therapeutics reported a loss per share of $0.1, significantly better than the estimated loss per share of $1.13. The company's financial results indicate a strong cash position of $1.25 billion, extending its runway into mid-2029. Revenue growth is anticipated at 33.8% next year, according to analysts' estimates.

Publication Date: Mar -09

📋 Highlights
  • BEAM-304 PKU Program: Targets two most prevalent PKU mutations (50% of patients) with preclinical data showing rapid normalization of phenylalanine levels and plans for IND filing in 2026.
  • Strategic Financing: $500M non-dilutive capital from Sixth Street supports risto-cel commercialization, alongside $1.25B cash balance extending runway to mid-2029.
  • Regulatory Flexibility: FDA supports "umbrella clinical trial" for multiple PAH variants under one IND, enabling efficient expansion to over 1,000 known PKU mutations.
  • Platform Scalability: Incremental cost reductions for adding new mutation-specific editors within BEAM-304, leveraging shared LNP delivery and base editing components.
  • In Vivo Sickle Cell Advancement: Prioritizing next-gen in vivo approach over ESCAPE, with 103 program in healthy volunteers focusing on antibody safety and comparable editing efficiency to HSC-based methods.

Financial Performance

The company's financials show a significant improvement in its cash balance, which is expected to support the commercialization of its potentially transformative therapies. The loss per share was $0.1, beating estimates, and the company's cash balance is $1.25 billion. The P/E Ratio is -34.13, and the P/S Ratio is 19.34, indicating that the stock may be overvalued.

Pipeline Progress

Beam Therapeutics is making progress in its pipeline, particularly with its BEAM-304 program, which targets phenylketonuria (PKU). The company is developing a one-time treatment for PKU patients using its base editing technology. According to Dr. Giuseppe Ciaramella, "We've seen a significant demand for a program like risto-cel. Patients are waiting to get treated." The company's approach involves developing multiple mutation-specific base editors within a single clinical program.

Regulatory Updates

The company has had productive pre-IND interactions with the FDA and plans to file the IND for BEAM-304 in 2026. The FDA is supportive of the company's platform approach for treating multiple variants. As Amy Simon stated, "We've had good meetings with the FDA, and they're supportive of our platform approach for treating multiple variants under one program or IND."

Valuation Metrics

The company's valuation metrics indicate that it may be overvalued. The P/E Ratio is -34.13, and the EV/EBITDA is -36.06. The ROE is -7.31%, and the ROIC is -27.43%. These metrics suggest that the company's stock price may be too high compared to its earnings and financial performance.

Conclusion

Beam Therapeutics is making progress in its pipeline and has a strong cash position to support its commercialization efforts. However, the company's valuation metrics indicate that it may be overvalued. As the company continues to develop its pipeline and advance its programs, investors should closely monitor its financial performance and progress in the clinic.

3. NewsRoom

Card image cap

Beam Therapeutics: Great Potential, But Patience Is Needed

Feb -27

Source: seekingalpha.com

Card image cap

BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

Feb -25

Source: zacks.com

Card image cap

Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

What's Going On With Beam Therapeutics Stock?

Feb -24

Source: benzinga.com

Card image cap

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates

Feb -24

Source: zacks.com

Card image cap

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Feb -24

Source: globenewswire.com

Card image cap

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Feb -24

Source: globenewswire.com

Card image cap

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Feb -23

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.43%)

6. Segments

Genetic Medicines

Expected Growth: 14.43%

Beam Therapeutics Inc.'s Genetic Medicines segment growth of 14.43% is driven by increasing adoption of gene editing technologies, rising prevalence of genetic disorders, and advancements in CRISPR-Cas9 gene editing. Additionally, strategic partnerships, expanding pipeline, and growing investments in research and development are contributing to the segment's rapid growth.

7. Detailed Products

Base Editing

A precise and efficient gene editing technology that enables the direct, irreversible conversion of one DNA base to another without making a double-stranded break in the genome.

Prime Editing

A highly efficient and precise gene editing technology that combines the precision of CRISPR-Cas9 with the efficiency of homology-directed repair.

Adeno-Associated Virus (AAV) Vectors

A viral vector technology used to deliver therapeutic genes to cells, enabling the treatment of genetic diseases.

CRISPR-Cas9 Gene Editing

A precise and efficient gene editing technology that enables the editing of genes by targeting specific sequences of DNA.

8. Beam Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Beam Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative gene editing technologies such as CRISPR and zinc finger nucleases. However, the company's proprietary base editing technology provides a unique value proposition that differentiates it from competitors.

Bargaining Power Of Customers

Beam Therapeutics Inc. has a low bargaining power of customers due to the lack of alternative treatment options for genetic diseases. This gives the company significant pricing power and negotiating leverage with customers.

Bargaining Power Of Suppliers

Beam Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment. However, the company's reliance on a few key suppliers for critical components may limit its negotiating power.

Threat Of New Entrants

Beam Therapeutics Inc. faces a high threat of new entrants due to the growing interest in gene editing technologies and the potential for new companies to enter the market. The company's proprietary technology and intellectual property provide some barriers to entry, but new entrants may still pose a significant threat.

Intensity Of Rivalry

Beam Therapeutics Inc. operates in a highly competitive industry with multiple companies developing gene editing technologies. The company faces intense rivalry from established players and new entrants, which may lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 15.00%
Debt Cost 13.34%
Equity Weight 85.00%
Equity Cost 13.34%
WACC 13.34%
Leverage 17.65%

11. Quality Control: Beam Therapeutics Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Stoke Therapeutics

A-Score: 4.3/10

Value: 1.0

Growth: 5.3

Quality: 7.6

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Agenus

A-Score: 4.1/10

Value: 9.4

Growth: 2.1

Quality: 4.6

Yield: 0.0

Momentum: 7.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
IGM Biosciences

A-Score: 4.1/10

Value: 9.6

Growth: 7.1

Quality: 4.0

Yield: 0.0

Momentum: 0.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Editas Medicine

A-Score: 3.6/10

Value: 6.4

Growth: 3.9

Quality: 3.6

Yield: 0.0

Momentum: 7.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Beam Therapeutics

A-Score: 3.2/10

Value: 6.7

Growth: 3.1

Quality: 3.7

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
AIM ImmunoTech

A-Score: 2.9/10

Value: 8.0

Growth: 4.3

Quality: 5.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

25.72$

Current Price

25.72$

Potential

-0.00%

Expected Cash-Flows